Profile change history

What changed for Maridebart cafraglutide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Maridebart cafraglutide identity.

25Total events
23Record additions
2Version changes
2Cited source years

Before and after

Preserved version changes

Profile status changed

Maridebart cafraglutide profile

We added a plain-language reader guide with cited answers, Phase 2 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 3 trials.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
Investigational
After
In clinical trials; not FDA-approved

Profile summary

Before
An antibody-peptide conjugate candidate. This profile cites a completed ClinicalTrials.gov study record.
After
An experimental Amgen antibody-peptide conjugate, also called MariTide, that blocks the GIP receptor and activates the GLP-1 receptor. It is in Phase 3 trials and not FDA-approved.

Evidence note

Before
ClinicalTrials.gov lists an Amgen bioavailability study as completed, updated July 21, 2026.
After
A large 52-week randomized Phase 2 trial reported weight loss compared with placebo in people with obesity, with common gastrointestinal side effects. Phase 3 trials, including a cardiovascular outcomes trial, are registered.

Cited source records

Before
ctg-nct07717814-v1
After
ctg-nct07717814-v1, journal-pmid-40549887, ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3, ctg-observation-nct07037433-2026-07-24-ae9704758762, ctg-observation-nct07037459-2026-07-02-199638062a19, ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e

Claim citations

Before
name: ctg-nct07717814-v1; aliases: ctg-nct07717814-v1; category: ctg-nct07717814-v1; status: ctg-nct07717814-v1; summary: ctg-nct07717814-v1; evidenceNote: ctg-nct07717814-v1
After
name: ctg-nct07717814-v1; aliases: ctg-nct07717814-v1; category: ctg-nct07717814-v1; status: ctg-nct07717814-v1, ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3, ctg-observation-nct07037433-2026-07-24-ae9704758762; summary: ctg-nct07717814-v1, journal-pmid-40549887, ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3; evidenceNote: journal-pmid-40549887, ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3, ctg-observation-nct07037433-2026-07-24-ae9704758762
Profile updated

Maridebart cafraglutide profile

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

PeptideScanner change date
July 27, 2026
Evidence lane
Profile

Profile summary

Before
An antibody-peptide conjugate candidate represented in ClinicalTrials.gov.
After
An antibody-peptide conjugate candidate. This profile cites a completed ClinicalTrials.gov study record.

Collection chronology

Evidence added to PeptideScanner

Browse all 23 connected records →

Showing the latest 23 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 14, 2026.

Record added

ClinicalTrials.gov record NCT06660173

PeptideScanner retained ClinicalTrials.gov record NCT06660173 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 11, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06858839

PeptideScanner retained ClinicalTrials.gov record NCT06858839 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 17, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07310563

PeptideScanner retained ClinicalTrials.gov record NCT07310563 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
November 14, 2026
Cited source date
October 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07832799

PeptideScanner retained ClinicalTrials.gov record NCT07832799 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 22, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07871409

PeptideScanner retained ClinicalTrials.gov record NCT07871409 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 9, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07908316

PeptideScanner retained ClinicalTrials.gov record NCT07908316 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 2, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07921316

PeptideScanner retained ClinicalTrials.gov record NCT07921316 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-06, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 6, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07575399

PeptideScanner retained ClinicalTrials.gov record NCT07575399 at 2026-09-09T19:17:17.083Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
September 9, 2026
Cited source date
August 27, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07684144

PeptideScanner retained ClinicalTrials.gov record NCT07684144 at 2026-09-09T19:17:17.403Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
September 9, 2026
Cited source date
September 3, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07313761

PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
August 14, 2026
Cited source date
August 7, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07684235

PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
August 14, 2026
Cited source date
August 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07037433

PeptideScanner retained ClinicalTrials.gov record NCT07037433 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
August 13, 2026
Cited source date
July 24, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07037459

PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
August 13, 2026
Cited source date
July 2, 2026
Evidence lane
Clinical trials
Record added

Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.

PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
August 13, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 41337722

PeptideScanner retained PubMed bibliographic metadata for PMID 41337722 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
March 4, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 41337723

PeptideScanner retained PubMed bibliographic metadata for PMID 41337723 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
March 4, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 41337724

PeptideScanner retained PubMed bibliographic metadata for PMID 41337724 at 2026-07-30T18:19:18.413Z. PubMed recorded a metadata revision date of 2025-12-03 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
December 3, 2025
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT06987695

PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
August 9, 2026
Cited source date
December 17, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07226765

PeptideScanner retained ClinicalTrials.gov record NCT07226765 at 2026-07-30T16:19:03.046Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
August 9, 2026
Cited source date
June 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07229157

PeptideScanner retained ClinicalTrials.gov record NCT07229157 at 2026-07-30T16:25:18.016Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
August 9, 2026
Cited source date
January 23, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07225686

PeptideScanner retained ClinicalTrials.gov record NCT07225686 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
August 8, 2026
Cited source date
June 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07441252

PeptideScanner retained ClinicalTrials.gov record NCT07441252 at 2026-07-30T16:19:03.063Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

PeptideScanner change date
August 8, 2026
Cited source date
June 18, 2026
Evidence lane
Clinical trials